Checkmate 017 and 057:
Kaplan-Meier Estimates of OS
Nivolumab
(n=135)
Docetaxel
(n=137)
Events, n (%)
110 (81)
128 (93)
Median OS, mo
(95% CI)
9.2
(7.3, 12.6)
6.0
(5.1, 7.3)
HR (95% CI)
0.62 (0.47, 0.80)
Nivolumab
(n=292)
Docetaxel
(n=290)
Events, n (%)
228 (78)
247 (85)
Median OS, mo
(95% CI)
12.2
(9.7, 15.1)
9.5
(8.1, 10.7)
HR (95% CI)
0.75 (0.63, 0.91)
Checkmate 057 (non-SQ NSCLC)
Nivolumab
Docetaxel
Number of patients at risk:
Nivolumab
Docetaxel
100
80
60
40
20
0
0 3 6
128
89
Time (Months)
21
30 33
39
OS (%)
18
9 12
24 27
36
292
290
233
243
194
194
97
53
18
6
6
3
0
0
112
66
171
150
148
111
81
45
46
25
0
1
15
2-yr OS=16%
Δ13%
2-yr OS=29%
1-yr OS=51%
Δ12%
1-yr OS=39%
Checkmate 017 (SQ NSCLC)
100
80
60
40
20
0
0 3 6
51
22
Time (Months)
21
30 33
39
OS (%)
18
9 12
24 27
36
135
137
113
104
86
69
34
14
14
6
7
4
0
0
38
17
69
46
57
33
29
11
19
9
1
1
15
Number of patients at risk
:
Nivolumab
Docetaxel
2-yr OS=23%
2-yr OS=8%
Δ15%
1-yr OS=42%
1-yr OS=24%
Δ18%
Based on February 2016 DBL. Symbols refer to censored observations. Minimum follow-up for survival: 24.2 months.
Borghaei H et al. Poster presentation at ASCO 2016. 9025.
Nivolumab
Docetaxel
